TANNQUILYNNE Trademark

Trademark Overview


On Wednesday, May 9, 2018, a trademark application was filed for TANNQUILYNNE with the United States Patent and Trademark Office. The USPTO has given the TANNQUILYNNE trademark a serial number of 87914117. The federal status of this trademark filing is REGISTERED as of Tuesday, March 30, 2021. This trademark is owned by SyneuRx International (Taiwan) Corp.. The TANNQUILYNNE trademark is filed in the Pharmaceutical Products category with the following description:

Therapeutic pharmaceutical for the treatment of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Phenol for pharmaceutical purposes; Plant extracts for medical, veterinary and pharmaceutical purposes; Syrups for pharmaceutical purposes for the treatment of dementia; Chemical preparations for pharmaceutical or medical purposes, namely, for treating neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Plant extracts for pharmaceutical purposes; Pharmaceutical preparations for treating sunburn; Chemical reagents for medical or veterinary purposes; Adjuvants for medical purposes; Animal feed additive for use as a nutritional supplement for medical purposes; Medicinal herbal extracts for medical purposes; Antibacteria...
tannquilynne

General Information


Serial Number87914117
Word MarkTANNQUILYNNE
Filing DateWednesday, May 9, 2018
Status700 - REGISTERED
Status DateTuesday, March 30, 2021
Registration Number6303591
Registration DateTuesday, March 30, 2021
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, January 12, 2021

Trademark Statements


Goods and ServicesTherapeutic pharmaceutical for the treatment of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Phenol for pharmaceutical purposes; Plant extracts for medical, veterinary and pharmaceutical purposes; Syrups for pharmaceutical purposes for the treatment of dementia; Chemical preparations for pharmaceutical or medical purposes, namely, for treating neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Plant extracts for pharmaceutical purposes; Pharmaceutical preparations for treating sunburn; Chemical reagents for medical or veterinary purposes; Adjuvants for medical purposes; Animal feed additive for use as a nutritional supplement for medical purposes; Medicinal herbal extracts for medical purposes; Antibacterial substances for medical purposes; Transdermal patches featuring medication for the treatment of neuropsychiatric disorders, namely, schizophrenia, depression, attention deficit disorder, mild cognitive impairment, dementia, bipolar disorder, and other central nervous system disorders; Nutritional food additives for medical purposes in the nature of natural food extracts derived from plant; Herbal extracts for medical purposes; Phytotherapy preparations for medical purposes; Appetite suppressants for medical purposes; Beverages containing tannic acid for use as a nutritional supplement; Liquid nutritional supplement; Dietary and nutritional supplements; Nutritional supplements in the form of capsules, tablets, caplets, powder, syrups, gummies and gels; Powdered nutritional supplement drink mix; Nutritional supplement meal replacement bars for boosting energy; Nutritional supplements consisting primarily of tannic acid; Dietary and nutritional supplements used for weight loss; Nutritional supplement shakes; Nutritional and dietary supplements formed and packaged as bars; Nutritional supplements in capsule form for dogs; Nutritional supplements; Nutritional supplement for eliminating toxins from the body; Nutritionally fortified water for medical purposes; Nutritionally fortified beverages for medical purposes; Vitamin fortified beverages for medical purposes; Vitamin enriched chewing gum for medical purposes; Soy protein for use as a nutritional supplement in various powdered and ready-to-drink beverages; Nutritional supplement in the nature of a nutrient-dense, protein-based drink mix; Powdered nutritional supplement drink mix containing tannic acid; Nutritional supplements for cats, dogs; Nutraceuticals for use as a dietary supplement for cognitive impairment; Nutraceuticals for the treatment of CNS disorders; Nutraceuticals for use as a dietary supplement

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateFriday, May 18, 2018
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameSYNEURX NEUROSCIENCE
Party Type31 - New Owner After Registration
Legal Entity Type16 - Limited Liability Company
AddressGRAND CAYMAN
KY

Party NameSyneuRx International (Taiwan) Corp.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressNew Taipei City 221
TW

Party NameSyneuRx International (Taiwan) Corp.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressNew Taipei City 221
TW

Party NameSyneuRx International (Taiwan) Corp.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressNew Taipei City 221
TW

Trademark Events


Event DateEvent Description
Saturday, May 12, 2018NEW APPLICATION ENTERED
Friday, May 18, 2018NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Thursday, August 30, 2018ASSIGNED TO EXAMINER
Wednesday, September 5, 2018NON-FINAL ACTION WRITTEN
Wednesday, September 5, 2018NON-FINAL ACTION E-MAILED
Wednesday, September 5, 2018NOTIFICATION OF NON-FINAL ACTION E-MAILED
Saturday, October 13, 2018TEAS RESPONSE TO OFFICE ACTION RECEIVED
Saturday, October 13, 2018CORRESPONDENCE RECEIVED IN LAW OFFICE
Saturday, October 13, 2018TEAS/EMAIL CORRESPONDENCE ENTERED
Monday, October 15, 2018APPROVED FOR PUB - PRINCIPAL REGISTER
Saturday, October 27, 2018ASSIGNED TO LIE
Wednesday, November 14, 2018NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, December 4, 2018PUBLISHED FOR OPPOSITION
Tuesday, December 4, 2018OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, January 29, 2019NOA E-MAILED - SOU REQUIRED FROM APPLICANT
Wednesday, July 17, 2019SOU TEAS EXTENSION RECEIVED
Wednesday, July 17, 2019SOU EXTENSION 1 FILED
Wednesday, July 17, 2019SOU EXTENSION 1 GRANTED
Friday, July 19, 2019NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, January 3, 2020SOU TEAS EXTENSION RECEIVED
Friday, January 3, 2020SOU EXTENSION 2 FILED
Friday, January 3, 2020SOU EXTENSION 2 GRANTED
Tuesday, January 7, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Friday, July 24, 2020TEAS CHANGE OF OWNER ADDRESS RECEIVED
Friday, July 24, 2020TEAS REVOKE/APP/CHANGE ADDR OF ATTY/DOM REP RECEIVED
Friday, July 24, 2020ATTORNEY/DOM.REP.REVOKED AND/OR APPOINTED
Friday, July 24, 2020TEAS CHANGE OF DOMESTIC REPRESENTATIVES ADDRESS
Friday, July 24, 2020TEAS CHANGE OF CORRESPONDENCE RECEIVED
Friday, July 24, 2020APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Sunday, July 26, 2020SOU TEAS EXTENSION RECEIVED
Sunday, July 26, 2020SOU EXTENSION 3 FILED
Sunday, July 26, 2020SOU EXTENSION 3 GRANTED
Tuesday, July 28, 2020NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED
Thursday, October 1, 2020TEAS PETITION TO AMEND BASIS RECEIVED
Monday, November 2, 2020ASSIGNED TO EXAMINER
Tuesday, December 1, 2020ASSIGNED TO PETITION STAFF
Wednesday, December 2, 2020PETITION TO DIRECTOR - CHANGE BASIS - GRANTED
Wednesday, December 2, 2020ATTORNEY REVIEW/DECISION ON AMENDMENT REQUIRED
Wednesday, December 9, 2020NOTICE OF ALLOWANCE CANCELLED
Wednesday, December 9, 2020CASE RETURNED TO EXAMINATION
Wednesday, December 23, 2020NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, January 12, 2021PUBLISHED FOR OPPOSITION
Tuesday, January 12, 2021OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, March 30, 2021REGISTERED-PRINCIPAL REGISTER
Wednesday, January 21, 2026AUTOMATIC UPDATE OF ASSIGNMENT OF OWNERSHIP